Osimertinib-Induced Cardiomyopathy

Shruti R. Patel, MD; Sherry-Ann N. Brown, MD, PhD; Jilan E. Kubusek, PharmD, RPh; Aaron S. Mansfield, MD; Narjust Duma, MD

JACC: Case Reports (Apr 2020)

Osimertinib-Induced Cardiomyopathy

Shruti R. Patel, MD,
Sherry-Ann N. Brown, MD, PhD,
Jilan E. Kubusek, PharmD, RPh,
Aaron S. Mansfield, MD,
Narjust Duma, MD

Affiliations

Shruti R. Patel, MD: Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
Sherry-Ann N. Brown, MD, PhD: Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
Jilan E. Kubusek, PharmD, RPh: Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota
Aaron S. Mansfield, MD: Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota
Narjust Duma, MD: Division of Medical Oncology, University of Wisconsin, Madison, Wisconsin; Address for correspondence: Dr. Narjust Duma, University of Wisconsin, Division of Medical Oncology, 600 Highland Avenue, Madison, Wisconsin 53705.

Journal volume & issue: Vol. 2, no. 4
pp. 641 – 645

Abstract

Read online

Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.)

Published in JACC: Case Reports

ISSN: 2666-0849 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-case-reports

About the journal

Abstract

Keywords